Thanks to reader Julie for alerting me to this study which is currently recruiting participants. It is studying baminercept vs placebo in Sjögren's Syndrome and conducted by National Institute of Allergy and Infectious Diseases (NIAID). This from Clinicaltrials.gov:
The purpose of the study is to find out if the experimental study agent, baminercept, is effective in treating patients with Sjögren's syndrome. The study will also determine if the study agent can be safely given to patients with Sjögren's syndrome; examine how it affects symptoms of the disease; and attempt to understand how baminercept affects the underlying mechanisms of Sjögren's syndrome and the immune system.
You can read more about study number NCT01552681 and search for other Sjogren's related studies here. Baminercept is a dual-mechanism, lymphotoxin-b (LT-b) and LIGHT pathway inhibitor. You can read more about baminercept here.
You can read about other current Sjogren's syndrome studies on the National Institutes of Health ClinicalTrials.gov site, here.
(This post edited. I had previously identified baminercept as a TNF inhibitor, which was incorrect.)
No comments:
Post a Comment